关键词: 吉西他滨, 雄激素非依赖性前列腺癌, PC3细胞, PARP抑制剂, 多西他赛

Abstract:

Objective  To explore the effect of PARP inhibitor AG014699 combined with  Gemcitabine or Docetaxel on the proliferation of androgen-independent prostate cancer cell line PC3. Methods  PC3 cells were cultured in vitro and then divided into PARP inhibitor group, Gemcitabine group, Docetaxel group, combination of PARP inhibitor and Gemcitabine group, combination of PARP inhibitor and Docetaxel group. CCK-8 method was used to assess the vitality of PC3 cells after different treatments; flow cytometry was adopted to determine apoptosis and distribution of cell cycle after PC3 cells were treated with PARP inhibitor. Results  PARP inhibitor AG014699 showed significant anti-proliferative effects on PC3 cells in a dose-and-time dependent pattern (P<0.05); Gemcitabine or Docetaxel inhibited the growth of PC3 cells in a dose dependent manner (P<0.05); compared with Gemcitabine or Docetaxel used alone, combination of PARP inhibitor and Gemcitabine or Docetaxel could significantly inhibit the growth of PC3 cells (P<0.05). Conclusion  PARP inhibitor AG014699 combined with Gemcitabine or Docetaxel has a synergistic antitumor effect on androgen-independent prostate cancer cell line PC3, which may become a promising therapy for androgen-independent prostate cancer.  

Key words: Androgen-independent prostate cancer, Gemcitabine, PC3 cells, PARP inhibitor, Docetaxel